Acute promyelocytic leukemia pathophysiology: Difference between revisions
Shyam Patel (talk | contribs) No edit summary |
Shyam Patel (talk | contribs) No edit summary |
||
| Line 11: | Line 11: | ||
|valign=top| | |valign=top| | ||
|+ | |+ | ||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF| | ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Translocation Partner}} | ||
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Chromosomal Location}} | ! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Chromosomal Location}} | ||
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Function}} | ! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Function}} | ||
| Line 32: | Line 32: | ||
5q35.1 | 5q35.1 | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
* | *Encodes nucleophosmin 1 (a nucleolar shuttle protein) | ||
*Involved in centromere duplication | |||
*[[ | *Serves a protein chaperone | ||
* | *Regulates the cell cycle | ||
*Sequesters the tumor suppressor ''ARF'' in the nucleus and protects ''ARF'' from degradation | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*''NPM1'' mutation carries a favorable prognosis in [[acute myeloid leukemia]] | |||
*Rare translocation | |||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | ||
Revision as of 21:35, 10 May 2018
|
Acute promyelocytic leukemia Microchapters |
|
Differentiating Acute promyelocytic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acute promyelocytic leukemia pathophysiology On the Web |
|
American Roentgen Ray Society Images of Acute promyelocytic leukemia pathophysiology |
|
Directions to Hospitals Treating Acute promyelocytic leukemia |
|
Risk calculators and risk factors for Acute promyelocytic leukemia pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]
Pathophysiology
The pathophysiology of acute promyelocytic leukemia begins with a balanced reciprocal chromosomal translocation in hematopoietic stem cells. The chromosomal translocation involves the juxtaposition of the retinoic acid receptor-alpha gene (RARA) on the long arm of chromosome 17 with another gene, most commonly the promyelocytic leukemia gene (PML) on the long arm of chromosome 15.[1] The translocation is designated as t(15;17)(q22;q12). The PML-RARA fusion product is a transcriptional regulator and prevents myeloid differentiation. This is known as a differentiation block, since the cells are unable to differentiate into normal mature cells. The result of the chromosomal translocation is ineffective blood cell production and uncontrolled proliferation of malignant promyelocytes.[1] In 95% of cases of acute promyelocytic leukemia, the translocation involved PML and RARA. However, it is important to note that RARA has multiple other binding partners which can lead to the development or acute promyelocytic leukemia.
Four other gene rearrangements have been described in APL fusing RARα to promyelocytic leukemia zinc finger (PLZF or ZBTB16), nucleophosmin (NPM), nuclear matrix associated (NUMA), or signal transducer and activator of transcription 5b (STAT5B) genes., ZBTB16
| Translocation Partner | Chromosomal Location | Function | Other Features |
|---|---|---|---|
|
PLZF (ZBTB16) |
11q23.2 |
|
|
|
NPM1 |
5q35.1 |
|
|
|
Mixed warm-antibody and cold-antibody type |
|
|
References
- ↑ 1.0 1.1 Langabeer SE, Preston L, Kelly J, Goodyer M, Elhassadi E, Hayat A (2017). "Molecular Profiling: A Case of ZBTB16-RARA Acute Promyelocytic Leukemia". Case Rep Hematol. 2017: 7657393. doi:10.1155/2017/7657393. PMC 5424191. PMID 28529810.